3月6日,辉瑞中国宣布,国家药监局正式批准新药埃诺格鲁肽注射液,用于成人超重和肥胖患者的长期体重管理。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.